COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom
Among people with major cardiometabolic conditions, there have been substantial reductions in the assessment and control of several key RFs during the pandemic. These patients will need regular monitoring in future for the prevention of complications. Our findings also highlight the need for resilient healthcare systems to ensure continuity of care and mitigate disparities in high-risk populations.
Authors
- Thomas Yates (ORCID: https://orcid.org/0000-0001-5287-447X)
- Cameron Razieh (ORCID: https://orcid.org/0000-0003-3597-2945)
- Clare L. Gillies (ORCID: https://orcid.org/0000-0002-8417-9700)
- Samuel Seidu (ORCID: https://orcid.org/0000-0002-8335-7018)
- Nazrul Islam (ORCID: https://orcid.org/0000-0003-3982-4325)
- Amitava Banerjee (ORCID: https://orcid.org/0000-0001-8741-3411)
- Sharmin Shabnam (ORCID: https://orcid.org/0000-0002-2519-1240)
- Francesco Zaccardi (ORCID: https://orcid.org/0000-0002-2636-6487)
- Kamlesh K. Khunti (ORCID: https://orcid.org/0000-0003-2343-7099)
- Yogini Chudasama (ORCID: https://orcid.org/0000-0002-6777-0064)
Institutions
- Office for National Statistics (GB)
- University of Leicester (GB)
- NIHR Southampton Biomedical Research Centre (GB)
- NIHR Leicester Biomedical Research Centre (GB)
- University of Southampton (GB)
- University College London (GB)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1371/journal.pone.0319438
- Citations
- 2
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Alan Turing Institute
- UK Research and Innovation
- National Institute for Health and Care Research
- University of Leicester
- Daiichi-Sankyo
- Novo Nordisk
- Engineering and Physical Sciences Research Council
- NIHR Leicester Biomedical Research Centre